NCT01621204 - A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2019

Study Completion Date

August 31, 2019

Conditions

Immune Thrombocytopenic Purpura

Interventions

DRUG

Eltrombopag

Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).

DRUG

IVIG infusion

IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed

Trial Locations (10)

T6G2G3

University of Alberta Hospital, Edmonton

V5Z1M9

Vancouver General Hospital, Vancouver

L8N 3Z5

Hamilton Health Sciences, Hamilton

N6A5W9

London Health Sciences Center, London

K1H8L6

Ottawa Hospital, Ottawa

M4N3M5

Sunnybrook Hospital, Toronto

M5B1W8

St.Micheal's Hospital, Toronto

H1T2M4

Hopital Maisonneuve-Rosemont, Montreal

H3T1E2

Jewish General Hospital, Montreal

Unknown

The Haga Hospital, The Hague